ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 90 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2020. The put-call ratio across all filers is 0.71 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,559,640 | -36.1% | 9,699,925 | 0.0% | 13.20% | -49.9% |
| Q2 2023 | $72,846,437 | +66.2% | 9,699,925 | 0.0% | 26.36% | +8.5% |
| Q1 2023 | $43,843,661 | -59.9% | 9,699,925 | 0.0% | 24.30% | -28.3% |
| Q4 2022 | $109,318,155 | +17.8% | 9,699,925 | 0.0% | 33.89% | +57.8% |
| Q3 2022 | $92,828,000 | +18.3% | 9,699,925 | 0.0% | 21.48% | -3.9% |
| Q2 2022 | $78,472,000 | -52.1% | 9,699,925 | 0.0% | 22.34% | -38.5% |
| Q1 2022 | $163,929,000 | -21.4% | 9,699,925 | 0.0% | 36.34% | -3.2% |
| Q4 2021 | $208,451,000 | -70.9% | 9,699,925 | 0.0% | 37.56% | -47.4% |
| Q3 2021 | $716,436,000 | +35.1% | 9,699,925 | 0.0% | 71.38% | +14.0% |
| Q2 2021 | $530,392,000 | -25.8% | 9,699,925 | 0.0% | 62.60% | -7.9% |
| Q1 2021 | $715,272,000 | -14.5% | 9,699,925 | 0.0% | 67.97% | -7.9% |
| Q4 2020 | $836,134,000 | +128.4% | 9,699,925 | 0.0% | 73.80% | +32.7% |
| Q3 2020 | $366,075,000 | – | 9,699,925 | – | 55.63% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $46,559,640 | 13.20% |
| Vivo Capital, LLC | 4,220,048 | $20,256,230 | 2.22% |
| Logos Global Management LP | 1,000,000 | $4,800,000 | 0.64% |
| Orbimed Advisors | 2,871,000 | $13,780,800 | 0.29% |
| Redmile Group, LLC | 1,283,289 | $6,159,787 | 0.29% |
| BRAIDWELL LP | 1,249,900 | $5,999,520 | 0.19% |
| Cormorant Asset Management, LP | 612,079 | $2,937,979 | 0.17% |
| Nan Fung Group Holdings Ltd | 41,950 | $201,360 | 0.16% |
| Forefront Analytics, LLC | 13,769 | $66,092 | 0.04% |
| CORNERCAP INVESTMENT COUNSEL INC | 35,071 | $168,341 | 0.03% |